Intestinal obstruction in patients receiving peptide receptor radionuclide therapy for gastroentero-pancreatic neuroendocrine tumors: potential predictors and association with overall survival

被引：0
|
作者：
Badawy, Mohamed
Johnson, Geoffrey [1 ]
Wee, Christopher [2 ]
Halfdanarson, Thorvardur R. [1 ]
Abdelrazek, Ahmad [1 ]
Packard, Ann [1 ]
Jain, Manoj
Thorpe, Matthew [1 ]
Kendi, Ayse [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Cleveland Clin, Cleveland, OH USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P439
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Quality Of Life in Patients with Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy
    Wang, Q.
    Librizzi, D.
    Bagheri, S.
    Ebrahimifard, A.
    Luster, M.
    Yousefi, B. H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S246 - S247
  • [22] Neoadjuvant Downsizing by Internal Radiation A Case for Preoperative Peptide Receptor Radionuclide Therapy in Patients With Pancreatic Neuroendocrine Tumors
    Ezziddin, Samer
    Lauschke, Holger
    Schaefers, Michael
    Meyer, Carsten
    van Essen, Martijn
    Biersack, Hans-Juergen
    Kwekkeboom, Dik J.
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2012, 37 (01) : 102 - 104
  • [23] Long term results of Peptide Receptor Radionuclide Therapy of progressive pancreatic neuroendocrine tumors (pNET)
    Prasad, V.
    Zachert, C.
    Hoersch, D.
    Hommann, M.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S351 - S351
  • [24] Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors
    Gujarathi, Rushabh
    Tobias, Joseph
    Abou Azar, Sara
    Keutgen, Xavier M.
    Liao, Chih-Yi
    CANCERS, 2024, 16 (17)
  • [25] Peptide receptor radionuclide therapy versus capecitabine/ temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors
    Gujarathi, R.
    Tobias, J.
    Azar, S. A.
    Keutgen, X.
    Liao, C-Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S94 - S94
  • [26] Hyponatremia and hypernatremia have an opposing effect on overall survival in neuroendocrine tumor patients treated with peptide receptor radionuclide therapy
    Refardt, J.
    Brabander, T.
    Minczeles, N. S.
    Feelders, R. A.
    de Herder, W. W.
    Hofland, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 78 - 78
  • [27] Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 171 - 171
  • [28] Peptide receptor radionuclide therapy in patients with pulmonary neuroendocrine tumors: our experience.
    Minutoli, F.
    Cardile, D.
    Cucinotta, M.
    Quartuccio, N.
    Gangemi, V.
    Sindoni, A.
    Baldari, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S531 - S531
  • [29] Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
    Kobayashi, Noritoshi
    Wild, Damian
    Kaul, Felix
    Shimamura, Takeshi
    Takano, Shoko
    Takeda, Yuma
    Okubo, Naoki
    Suzuki, Akihiro
    Tokuhisa, Motohiko
    Ichikawa, Yasushi
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2021, 28 (09) : 727 - 739
  • [30] Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors
    Riff, Brian P.
    Yang, Yu-Xiao
    Soulen, Michael C.
    Pryma, Daniel A.
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina R.
    Metz, David C.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : 845 - 850
12345